0001048477-24-000010.txt : 20240212 0001048477-24-000010.hdr.sgml : 20240212 20240212172005 ACCESSION NUMBER: 0001048477-24-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240118 FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 24621312 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 wk-form4_1707776385.xml FORM 4 X0508 4 2024-01-18 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO STREET SAN RAFAEL CA 94901 1 0 0 0 1 Common Stock 2024-01-18 4 L 0 40 92.5975 A 419602 D Common Stock 2024-02-08 4 M 0 15000 63.10 A 434602 D Common Stock 2024-02-08 4 S 0 15000 89.77 D 419602 D Common Stock 2024-02-09 4 M 0 15000 63.10 A 434602 D Common Stock 2024-02-09 4 S 0 15000 88.28 D 419602 D Common Stock 247333 I Shares held by Jean-Jacques Bienaime Family Trust Common Stock 100 I Shares held as UTMA custodian for child 1 Common Stock 100 I Shares held as UTMA custodian for child 2 Stock Option (Right to Buy Common Stock) 63.10 2024-02-08 4 M 0 15000 0 D 2014-12-04 2024-06-03 Common Stock 15000 146000 D Stock Option (Right to Buy Common Stock) 63.10 2024-02-09 4 M 0 15000 0 D 2014-12-04 2024-06-03 Common Stock 15000 131000 D The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 40 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. The price in column 4 is the weighted average price. The purchase price actually paid ranged from $92.595 to $92.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Tae Sang Yoo, Attorney-in-Fact 2024-02-12